Literature DB >> 3264656

Cystic fibrosis in Denmark 1945 to 1985. An analysis of incidence, mortality and influence of centralized treatment on survival.

O H Nielsen1, B L Thomsen, A Green, P K Andersen, M Hauge, P O Schiøtz.   

Abstract

The entire population of cystic fibrosis (CF) patients in Denmark diagnosed in the period January 1, 1945, to June 30, 1985, comprised 514 persons of whom 62 were diagnosed at autopsy. Of the remaining 452 patients, 372 were probands and 80 were secondary cases. The effect of a centralized treatment on the prognosis was evaluated using a Cox's regression model. Furthermore an incidence analysis was performed using probands including autopsies. Centralized treatment had a significantly beneficial effect on the prognosis (p = 0.02), the death intensity (hazard rate) being decreased by a factor of 0.60. It was calculated that at present 1 out of 4,760 newborn Danes may be diagnosed as suffering from CF before the age of 15 years, and 3% of the Danish population are heterozygotes for CF.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264656     DOI: 10.1111/j.1651-2227.1988.tb10765.x

Source DB:  PubMed          Journal:  Acta Paediatr Scand        ISSN: 0001-656X


  11 in total

1.  Gradient of distribution in Europe of the major CF mutation and of its associated haplotype. European Working Group on CF Genetics (EWGCFG).

Authors: 
Journal:  Hum Genet       Date:  1990-09       Impact factor: 4.132

Review 2.  Shared care--is it worth it for the patient?

Authors:  Iolo Doull
Journal:  J R Soc Med       Date:  2012-06       Impact factor: 5.344

3.  Standards of care for children with cystic fibrosis--a personal view.

Authors:  G A Gregory
Journal:  J R Soc Med       Date:  1994       Impact factor: 5.344

4.  Transmitting genetic risk information in families: attitudes about disclosing the identity of relatives.

Authors:  J T Wilcke; N Seersholm; A Kok-Jensen; A Dirksen
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

5.  Increased adherence to CFF practice guidelines for pulmonary medications correlates with improved FEV1.

Authors:  Brooke M Moore; Theresa A Laguna; Meixia Liu; John J McNamara
Journal:  Pediatr Pulmonol       Date:  2012-09-19

6.  Assessing Differences in Mortality Rates and Risk Factors Between Hispanic and Non-Hispanic Patients With Cystic Fibrosis in California.

Authors:  MyMy C Buu; Lee M Sanders; Jonathan A Mayo; Carlos E Milla; Paul H Wise
Journal:  Chest       Date:  2016-01-12       Impact factor: 9.410

7.  394delTT: a Nordic cystic fibrosis mutation.

Authors:  M Schwartz; M Anvret; M Claustres; H G Eiken; K Eiklid; C Schaedel; L Stolpe; L Tranebjaerg
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

8.  High incidence of cystic fibrosis on the Faroe Islands: a molecular and genealogical study.

Authors:  M Schwartz; N Sørensen; N J Brandt; E Høgdall; T Holm
Journal:  Hum Genet       Date:  1995-06       Impact factor: 4.132

9.  Existing data sources for clinical epidemiology: Danish registries for studies of medical genetic diseases.

Authors:  Mary Nguyen-Nielsen; Elisabeth Svensson; Ida Vogel; Vera Ehrenstein; Lone Sunde
Journal:  Clin Epidemiol       Date:  2013-08-08       Impact factor: 4.790

10.  Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre.

Authors:  James M Roberts; Pearce G Wilcox; Bradley S Quon
Journal:  Can Respir J       Date:  2016-02-29       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.